Trial · NCT03688971
Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
NCT03688971, Phase 2, Unknown, Maruho Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis. Trials, record NCT03688971. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03688971
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis
- NCT number
- NCT03688971
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 36 participants, estimated
- Lead sponsor
- Maruho Co., Ltd.
- Conditions
- Seborrheic Dermatitis
- Interventions
- Omiganan, Ketoconazole, Placebo
- First posted
- 2018-09-28
- Last updated
- 2019-05-01
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Seborrheic dermatitis area severity index (SDASI) | 6 Weeks | Assessment of erythema, scales and papules and each are scored as 0=none to 3=severe. |
| Primary | Investigator global assessment (IGA) | 6 Weeks | This is a 5-point scale ranging from 0=clear to 4=severe. |
| Primary | Area of involvement | 6 Weeks | Facial area involvement is estimated as a % of the body surface area (BSA) |
| Primary | Patient Reported Outcome (PRO) - eDiary | 4 Weeks | Single-question assessment regarding patient's worst itch. On a scale of 0-100, 0=no itch and 100=worst itch. |
| Primary | PRO - 5-D itch scale | 6 Weeks | Multidimensional measure of itching. Covers 5 domains: duration, degree, direction, disability and distribution. |
| Primary | PRO - dermatology life quality index (DLQI) | 6 Weeks | Asses health-related quality of life in general dermatology disability index |
| Primary | Standardized photography | 6 Weeks | Facial photographs will be taken by a 2D camera (VISIA-CR) |
| Primary | Sebum measurements | 6 Weeks | Measurement of sebum excretion by Sebumeter |
| Primary | Trans Epidermal Water Loss (TEWL) | 6 Weeks | To assess barrier status of lesional and non-lesional skin. |
| Primary | Optical Coherence Tomography (OCT) | 6 Weeks | Measurement of cutaneous morphology of seborrheic dermatitis |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03688971
GET https://conductscience.org/api/trials/v1/NCT03688971/registered?page=2